ELVN-001 (ENABLE)
ELVN-001 is an investigational medicine being studied for adults with chronic phase CML. It is designed to target the BCR::ABL1 protein while limiting effects on other proteins in the body. Researchers hope this may help reduce certain side effects seen with some other CML treatments. ELVN-001 is taken by mouth once daily and may be taken with or without food. ELVN-001 has not been approved for use.














